Drug Profile

IMU 856

Alternative Names: IMU-856

Latest Information Update: 05 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Daiichi Sankyo Company
Developer Immunic; Immunic Australia
Class Anti-inflammatories; Small molecules
Mechanism of Action SIRT6 protein modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Coeliac disease
No development reported Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

20 Feb 2025 Efficay data from phase I trial in Coeliac disease released by Immunic
13 Nov 2024 9429494 - Updated KDM for planned trial
15 Oct 2023 Efficacy, adverse events and pharmacokinetics data from a phase Ib trial in Coeliac disease released by Immunic

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com